Newer generations of antimyeloma drugs
| Mechanism/Target . | Drugs . |
|---|---|
| Proteasome inhibitors | Carfilzomib |
| Ixazomib | |
| Immunomodulatory drug | Pomalidomide |
| PI3K/AKT/mTOR inhibitors | Temsirolimus |
| Everolimus | |
| Perifosine | |
| Histone deacetylase inhibitor | Panobinostat |
| Vorinostat | |
| Alkylating plus purine analog | Bendamustine |
| p38/JNK activators | Plitidepsin |
| Hypoxia-activated alkylator | TH-302 |
| DNA-damaging agents | Zalypsis |
| Kinesin spindle protein inhibitor | Arry-520 |
| Monoclonal antibodies | Elotuzumab |
| Daratumumab | |
| SAR650984 |
| Mechanism/Target . | Drugs . |
|---|---|
| Proteasome inhibitors | Carfilzomib |
| Ixazomib | |
| Immunomodulatory drug | Pomalidomide |
| PI3K/AKT/mTOR inhibitors | Temsirolimus |
| Everolimus | |
| Perifosine | |
| Histone deacetylase inhibitor | Panobinostat |
| Vorinostat | |
| Alkylating plus purine analog | Bendamustine |
| p38/JNK activators | Plitidepsin |
| Hypoxia-activated alkylator | TH-302 |
| DNA-damaging agents | Zalypsis |
| Kinesin spindle protein inhibitor | Arry-520 |
| Monoclonal antibodies | Elotuzumab |
| Daratumumab | |
| SAR650984 |
JNK, c-Jun N-terminal kinase; mTOR, mammalian target of rapamycin; PI3K, phosphatidylinositol 3-kinase.